Page last updated: 2024-10-30

khellin and Acne

khellin has been researched along with Acne in 47 studies

Khellin: A vasodilator that also has bronchodilatory action. It has been employed in the treatment of angina pectoris, in the treatment of asthma, and in conjunction with ultraviolet light A, has been tried in the treatment of vitiligo. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1024)
khellin : A furanochrome in which the basic tricyclic skeleton is substituted at positions 4 and 9 with methoxy groups and at position 7 with a methyl group. A major constituent of the plant Ammi visnaga it is a herbal folk medicine used for various illnesses, its main effect being as a vasodilator.

Research Excerpts

ExcerptRelevanceReference
"The aim of this study was to investigate the prevalences of hypertrophic scars and keloids in acne patients treated with oral isotretinoin."7.83Observational retrospective study evaluating the effects of oral isotretinoin in keloids and hypertrophic scars. ( Bagatin, E; Gonçalves, RG; Guadanhim, LR, 2016)
"Isotretinoin-induced keloid formation has occasionally been reported in patients who have undergone dermabrasion or laser treatment."7.73Possible isotretinoin-induced keloids in a patient with Behçet's disease. ( Dogan, G, 2006)
"We report the observation of delayed wound healing and keloid formation in three patients, following dermabrasion or Argon laser treatment administered while they were receiving isotretinoin for acne or rosacea."7.67Delayed wound healing and keloid formation following argon laser treatment or dermabrasion during isotretinoin treatment. ( Zachariae, H, 1988)
"A case report of massive mandibular keloid with severe infection induced by acne achieved resolution of skin lesions after combined treatment with surgery and high concentration single-dose 5-aminolevulinic acid photodynamic therapy (5-ALA PDT)."4.02A massive mandibular keloid with severe infection: What is your treatment? ( Chen, XD; Gao, LM; Wu, XY; Zhao, LT, 2021)
"The aim of this study was to investigate the prevalences of hypertrophic scars and keloids in acne patients treated with oral isotretinoin."3.83Observational retrospective study evaluating the effects of oral isotretinoin in keloids and hypertrophic scars. ( Bagatin, E; Gonçalves, RG; Guadanhim, LR, 2016)
"Isotretinoin-induced keloid formation has occasionally been reported in patients who have undergone dermabrasion or laser treatment."3.73Possible isotretinoin-induced keloids in a patient with Behçet's disease. ( Dogan, G, 2006)
"We report the observation of delayed wound healing and keloid formation in three patients, following dermabrasion or Argon laser treatment administered while they were receiving isotretinoin for acne or rosacea."3.67Delayed wound healing and keloid formation following argon laser treatment or dermabrasion during isotretinoin treatment. ( Zachariae, H, 1988)
"Cryoanesthesia is ideally intended to cool only the epidermis during treatment and has advantage which did not require application time."3.30Cold anesthesia for pain reduction during intralesional steroid injection for nodulocystic acne. ( Kim, GH; Koh, YG; Park, KY; Park, SJ; Rho, NK; Shin, SH, 2023)
" No serious adverse reactions and good tolerability were reported in the included studies."3.01Efficacy and safety of needle-free jet injector-assisted intralesional treatments in dermatology-a systematic review. ( Bekkers, VZ; Bik, L; Prens, EP; van Doorn, MBA; van Huijstee, JC; Wolkerstorfer, A, 2023)
"Hypertrophic scars and keloids may complicate wound healing secondary to trauma or surgery."2.69Treatment of inflamed hypertrophic scars using intralesional 5-FU. ( Fitzpatrick, RE, 1999)
"Acne scarring can be classified into atrophic icepick, boxcar, and rolling scars in addition to keloidal and hypertrophic scars."2.53Acne Scar Treatment: A Multimodality Approach Tailored to Scar Type. ( Fabi, SG; McGraw, T; Taylor, M; Zaleski-Larsen, LA, 2016)
"Acne scarring is common but difficult to treat."2.46[Therapy of acne scars]. ( Jansen, T; Podda, M, 2010)
"The use of several modalities for the treatment of acne scarring is advocated; these include dermabrasion, punch-transplant replacement techniques, and collagen implants."2.36Cosmetic dermatologic surgery. ( Stegman, SJ; Tromovitch, TA, 1982)
" Combined with knowledge of the relevant literature, the mechanisms, types, and timing and dose, and reflect on balancing of recurrence rates and complications to deepen our understanding of the disease."1.91Rare Complication of Massive Depigmentation After Postoperative Treatment of Giant Keloid Combined With Strontium-90. ( Li, J; Liu, J; Wang, X; Wang, Y; Zhang, W; Zhang, Z, 2023)
"Acne vulgaris is a troubling skin disease known to have both physiologic and psychological effects on patients."1.72Acne Scars: An Update on Management ( Alajmi, A; Alazemi, M; Jfri, A; Ladha, MA, 2022)
"Keloid was identified in 13 boys and 10 girls, accounting for 0."1.34Prevalence of childhood acne, ephelides, warts, atopic dermatitis, psoriasis, alopecia areata and keloid in Kaohsiung County, Taiwan: a community-based clinical survey. ( Chen, W; Cheng, YW; Lai, CS; Yang, YC, 2007)
"Severe cases of nuchal AM may precede acne keloidalis nuchae (AKN)."1.30Prevalence of acne keloidalis nuchae in football players. ( Gonin, R; Hanke, CW; Knable, AL, 1997)
"In the childhood population, atopic eczema and tinea capitis were the most frequent dermatoses, comprising 63% of diagnoses recorded."1.30A study of the spectrum of skin disease occurring in a black population in south-east London. ( Child, FJ; Du Vivier, AW; Fuller, LC; Higgins, EM, 1999)
"Significant scarring is a potential sequela of the second degree burns produced by argon or carbon dioxide laser surgery, and is particularly a risk for children."1.27Laser surgery for children. ( Brauner, GJ; Schliftman, A, 1987)
"Indications for radiotherapy of benign dermatoses have decreased markedly during the past decades."1.26[Roentgen therapy of dermatoses: indications and hazards]. ( Goldschmidt, H, 1978)

Research

Studies (47)

TimeframeStudies, this research(%)All Research%
pre-199020 (42.55)18.7374
1990's8 (17.02)18.2507
2000's4 (8.51)29.6817
2010's5 (10.64)24.3611
2020's10 (21.28)2.80

Authors

AuthorsStudies
Goodman, GJ1
Liu, Y1
Li, Z1
Hu, J1
Zhan, S1
Wang, M1
Wang, L1
Chiriac, A1
Wollina, U1
Jfri, A2
Alajmi, A2
Alazemi, M2
Ladha, MA2
Ludwig, RJ1
von Stebut, E1
Bekkers, VZ1
Bik, L1
van Huijstee, JC1
Wolkerstorfer, A1
Prens, EP1
van Doorn, MBA1
Park, SJ1
Shin, SH1
Koh, YG1
Kim, GH1
Rho, NK1
Park, KY1
Liu, J1
Zhang, Z1
Wang, X1
Li, J1
Zhang, W1
Wang, Y1
Zhao, LT1
Gao, LM1
Chen, XD1
Wu, XY1
Scheiba, N1
Hartschuh, W1
Yeung, H1
Kahn, B1
Ly, BC1
Tangpricha, V1
Mitbauerová, A1
Čapek, L1
Ogawa, R1
Zaleski-Larsen, LA1
Fabi, SG1
McGraw, T1
Taylor, M1
Guadanhim, LR1
Gonçalves, RG1
Bagatin, E1
Thiboutot, D1
Gollnick, H1
Bettoli, V1
Dréno, B1
Kang, S1
Leyden, JJ1
Shalita, AR1
Lozada, VT1
Berson, D1
Finlay, A1
Goh, CL1
Herane, MI1
Kaminsky, A1
Kubba, R1
Layton, A1
Miyachi, Y1
Perez, M1
Martin, JP1
Ramos-E-Silva, M1
See, JA1
Shear, N1
Wolf, J1
Jansen, T1
Podda, M1
Taylor, SC1
Kelly, AP1
Dupree, NE1
Kimball, AB1
Lawrence, RC1
DE STEFANO, C1
WHEATE, HW1
WOODMAN, EN1
VIGLIOGLIA, PA1
KUHN, BH1
WALLACE, HJ1
Dogan, G1
Yang, YC1
Cheng, YW1
Lai, CS1
Chen, W1
Mukherjee, A2
Saha, KC1
Stegman, SJ2
Tromovitch, TA1
Thomas, JR1
Doyle, JA1
Sizov, VM1
Jutley, JK1
Ng, KY1
Cunliffe, WJ1
Layton, AM1
Wood, EJ1
Knable, AL1
Hanke, CW2
Gonin, R1
Fitzpatrick, RE1
Ginarte, M1
Peteiro, C1
Toribio, J1
Child, FJ1
Fuller, LC1
Higgins, EM1
Du Vivier, AW1
Rintala, AE1
Verbov, J1
Goldschmidt, H2
Lukacs, S1
Braun-Falco, O1
Harris, H1
Halber, S1
Salfeld, K1
Brauner, GJ1
Schliftman, A1
Zachariae, H1
Sherman, R1
Rosenfeld, H1
Rubenstein, R1
Roenigk, HH1
Walther, H1
Curth, W1
McSorley, J1
Dickinson, JT1
Rooker, DW1
Leonard, JR1

Clinical Trials (6)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Combined Treatment With Nonablative Fractional Laser and Radiofrequency Microneedling for the Treatment of Acne Scars: A Prospective, Randomized, Split-Face Study[NCT05105334]20 participants (Anticipated)Interventional2021-11-08Not yet recruiting
Open, Non-comparative, Multicentre Clinical Investigation to Evaluate the Performance and Safety of the Medical Device Plenhyage® (Polymerised Polynucleotides Dermal Filler) in the Treatment of Dermal Tissue Defects[NCT05239117]48 participants (Actual)Interventional2022-03-30Active, not recruiting
Comparison of Safety and Efficacy of Tazarotene 0.1% Plus Clindamycin 1% Gel vs. Adapalene 0.1% Plus Clindamycin 1% Gel in the Treatment of Facial Acne Vulgaris: A Randomized Controlled Trial[NCT02721173]Phase 460 participants (Actual)Interventional2016-04-30Completed
Autologous Fat Cells Transfer for the Treatment of Atrophic Post Acne Scars: Clinical Trail[NCT05028283]69 participants (Actual)Interventional2021-08-19Completed
A Phase 1B Dose Escalating Study of the Safety, Short-Term Engraftment and Action of a Singly-Applied NB01 in Adults With Moderate Acne[NCT03450369]Phase 110 participants (Actual)Interventional2018-01-24Completed
Serum apelin12 in Acne Vulgaris[NCT03480503]90 participants (Anticipated)Observational2018-05-31Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Number of Participants With Successful Engraftment of Probiotic Following a Single Application.

Engraftment is defined as the percentage of bacteria recovered from hair follicles that are health-associated (NB01) as measured with proprietary quantitative polymerase chain assays. Successful follicular engraftment, defined as both deoR/PanBac >40% and Cas5/PanBac >40% in the Day 2 (24H) ) Biore Strip samples. Cas5/PanBac and deoR/PanBac are the percentages of bacteria in a sample containing the CRISPR associated protein Cas5 and a repressor of porphyrin production deoR, respectively. Pan-Bacterial (PanBac) is a loci found in nearly all bacteria found on the face and thus serves as the denominator to calculate the percentage of bacteria with any loci. (NCT03450369)
Timeframe: 2 Months

InterventionParticipants (Count of Participants)
Low Dose2
High Dose1

Dose Schedule Determination Based on Time to Peak deoR and Cas5

To determine longevity of the live biotherapeutic after a single application, swab samples were collected at Baseline, 6, 24 and 48 hours after application, and genotyped as above. For each participant the absolute change, from Baseline, in the percentage of the two loci present in the live biotherapeutic (deoR and Cas5) were calculated. A significant positive change is indicative of the continued presence of the live biotherapeutic. (NCT03450369)
Timeframe: From Baseline to 48 hours after application

,
Intervention% of total bacteria w/ genotype (Mean)
Genotype 1 (deoR), 6 hoursGenotype 1 (deoR), 24 hoursGenotype 1 (deoR), 48 hoursGenotype 2 (Cas 5), 6 hoursGenotype 2 (Cas 5), 24 hoursGenotype 2 (Cas 5), 48 hours
High Dose51.25.22.848.44.41.8
Low Dose-0.4-4.213.812.83.43.2

Number of Participants With Change in Investigator Assessment of Tolerability Score: Conjunctival Injection

Safety profile and tolerability of a singly applied NB01 using the Investigator Assessment of Tolerability Scoring (0 = None; 1 = Slight; 2 = Moderate; 3 = Intense) for Conjunctival Injection. Reference: ClinicalTrials.gov: Investigator Assessment Tolerability Scoring: A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Acne. (NCT03450369)
Timeframe: From Screening to 28 days after application, typically 2 months

,
InterventionParticipants (Count of Participants)
Screening, scale = 0 (none)Day 1 (0 hours), scale = 0 (none)Day 1 (6 hours), scale = 0 (none)Day 2, scale = 0 (none)Day 3, scale = 0 (none)Day 7, scale = 0 (none)Day 28, scale = 0 (none)
High Dose5555555
Low Dose5555555

Number of Participants With Change in Investigator Assessment of Tolerability Score: Hyperpigmentation

Safety profile and tolerability of a singly applied NB01 using the Investigator Assessment of Tolerability Scoring (0 = None; 1 = Slight; 2 = Moderate; 3 = Intense) for Hyperpigmentation. Reference: ClinicalTrials.gov: Investigator Assessment Tolerability Scoring: A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Acne. (NCT03450369)
Timeframe: From Screening to 28 days after application, typically 2 months

,
InterventionParticipants (Count of Participants)
Screening, scale = 0 (none)Day 1 (0 hours), scale = 0 (none)Day 1 (6 hours), scale = 0 (none)Day 2, scale = 0 (none)Day 3, scale = 0 (none)Day 7, scale = 0 (none)Day 28, scale = 0 (none)
High Dose5555555
Low Dose5555555

Number of Participants With Change in Investigator Assessment of Tolerability Score: Irritant/Allergic Contact Dermatitis

Safety profile and tolerability of a singly applied NB01 using the Investigator Assessment of Tolerability Scoring (0 = None; 1 = Slight; 2 = Moderate; 3 = Intense) for Irritant/Allergic Contact Dermatitis. Reference: ClinicalTrials.gov: Investigator Assessment Tolerability Scoring: A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Acne. (NCT03450369)
Timeframe: From Screening to 28 days after application, typically 2 months

,
InterventionParticipants (Count of Participants)
Screening, scale = 0 (none)Day 1 (0 hours), scale = 0 (none)Day 1 (6 hours), scale = 0 (none)Day 2, scale = 0 (none)Day 3, scale = 0 (none)Day 7, scale = 0 (none)Day 28, scale = 0 (none)
High Dose5555555
Low Dose5555555

Number of Participants With Change in Investigator Assessment of Tolerability Score: Mucosal Toxicity

Safety profile and tolerability of a singly applied NB01 using the Investigator Assessment of Tolerability Scoring (0 = None; 1 = Slight; 2 = Moderate; 3 = Intense) for Mucosal Toxicity. Reference: ClinicalTrials.gov: Investigator Assessment Tolerability Scoring: A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Acne. (NCT03450369)
Timeframe: From Screening to 28 days after application, typically 2 months

,
InterventionParticipants (Count of Participants)
Screening, scale = 0 (none)Day 1 (0 hours), scale = 0 (none)Day 1 (6 hours), scale = 0 (none)Day 2, scale = 0 (none)Day 3, scale = 0 (none)Day 7, scale = 0 (none)Day 28, scale = 0 (none)
High Dose5555555
Low Dose5555555

Number of Participants With Change in Investigator Assessment of Tolerability Score: Ocular Irritation

Safety profile and tolerability of a singly applied NB01 using the Investigator Assessment of Tolerability Scoring (0 = None; 1 = Slight; 2 = Moderate; 3 = Intense) for Ocular Irritation. Reference: ClinicalTrials.gov: Investigator Assessment Tolerability Scoring: A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Acne. (NCT03450369)
Timeframe: From Screening to 28 days after application, typically 2 months

,
InterventionParticipants (Count of Participants)
Screening, scale = 0 (none)Day 1 (0 hours), scale = 0 (none)Day 1 (6 hours), scale = 0 (none)Day 2, scale = 0 (none)Day 3, scale = 0 (none)Day 7, scale = 0 (none)Day 28, scale = 0 (none)
High Dose5555555
Low Dose5555555

Number of Participants With Change in Investigator Assessment of Tolerability Score: Skin Dryness.

Safety profile and tolerability of a singly applied NB01 using the Investigator Assessment of Tolerability Scoring (0 = None; 1 = Slight; 2 = Moderate; 3 = Intense) for Skin Dryness. Reference: ClinicalTrials.gov: Investigator Assessment Tolerability Scoring: A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Acne. (NCT03450369)
Timeframe: From Screening to 28 days after application, typically 2 months

,
InterventionParticipants (Count of Participants)
Screening, scale = 0 (none)Screening, scale = 1 (slight)Day 1 (0 hours), scale = 0 (none)Day 1 (0 hours), scale = 1 (slight)Day 1 (6 hours), scale = 0 (none)Day 1 (6 hours), scale = 1 (slight)Day 2, scale = 0 (none)Day 2, scale = 1 (slight)Day 3, scale = 0 (none)Day 3, scale = 1 (slight)Day 7, scale = 0 (none)Day 28, scale = 0 (none)Day 28, scale = 1 (slight)
High Dose5050505050550
Low Dose4141414141532

Number of Participants With Change in Investigator Assessment of Tolerability Score: Skin Erythema.

Safety profile and tolerability of a singly applied NB01 using the Investigator Assessment of Tolerability Scoring (0 = None; 1 = Slight; 2 = Moderate; 3 = Intense) for Skin Erythema. Reference: ClinicalTrials.gov: Investigator Assessment Tolerability Scoring: A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Acne. (NCT03450369)
Timeframe: From Screening to 28 days after application, typically 2 months

,
InterventionParticipants (Count of Participants)
Screening, scale = 0 (none)Screening, scale = 1 (slight)Day 1 (0 hours), scale = 0 (none)Day 1 (0 hours), scale = 1 (slight)Day 1 (0 hours), scale = 2 (moderate)Day 1 (6 hours), scale = 0 (none)Day 1 (6 hours), scale = 1 (slight)Day 1 (6 hours), scale = 2 (moderate)Day 2, scale = 0 (none)Day 2, scale = 1 (slight)Day 3, scale = 0 (none)Day 3, scale = 1 (slight)Day 7, scale = 0 (none)Day 7, scale = 1 (slight)Day 28, scale = 0 (none)
High Dose505005005050505
Low Dose233113114141415

Number of Participants With Change in Investigator Assessment of Tolerability Score: Skin Peeling

Safety profile and tolerability of a singly applied NB01 using the Investigator Assessment of Tolerability Scoring (0 = None; 1 = Slight; 2 = Moderate; 3 = Intense) for Skin Peeling. Reference: ClinicalTrials.gov: Investigator Assessment Tolerability Scoring: A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Acne. (NCT03450369)
Timeframe: From Screening to 28 days after application, typically 2 months

,
InterventionParticipants (Count of Participants)
Screening, scale = 0 (none)Screening, scale = 1 (slight)Day 1 (0 hours), scale = 0 (none)Day 1 (0 hours), scale = 1 (slight)Day 1 (6 hours), scale = 0 (none)Day 1 (6 hours), scale = 1 (slight)Day 2, scale = 0 (none)Day 3, scale = 0 (none)Day 7, scale = 0 (none)Day 28, scale = 0 (none)
High Dose5050505555
Low Dose3241415555

Number of Participants With Change in Investigator Global Assessment (IGA) Score

"Number of participants with a changed Investigator Global Assessment (IGA) score after single application of NB01; positive number if grade is reduced (e.g. from 3 to 2) or negative number is IGA grade increased.~The Investigator Global Assessment 5-Point Score is a standard FDA acne assessment tool with scoring as follows:~Grade 0-Clear (Clear skin with no inflammatory or non-inflammatory lesions. The category of clear should represent true absence of disease) Grade1-Almost Clear (A few scattered comedones and no more than one small papule) Grade 2-Mild (Some comedones, some papules and pustules; no nodules) Grade 3-Moderate (Many comedones, papules and pustules; one nodule may be present) Grade 4-Severe (Covered with comedones, numerous papules and pustules and no more than a few nodular lesions)" (NCT03450369)
Timeframe: 28 Days

,
InterventionParticipants (Count of Participants)
Participants with changed IGA @ 6 hoursParticipants with changed IGA @ 1 dayParticipants with changed IGA @ 2 daysParticipants with changed IGA @ 6 daysParticipants with changed IGA @ 28 days
High Dose00000
Low Dose00002

Safety Profile and Tolerability of a Singly Applied NB01 Using Acne Lesion Counts.

Absolute Lesion Count: All Lesions for the Whole Face; with higher numbers of lesion representing worsening or more severe acne (NCT03450369)
Timeframe: From Screening to 28 days after application, typically 2 months

,
Interventioncount of lesions (Mean)
ScreeningDay 1 (0 hours)Day 1 (6 hours)Day 2Day 3Day 7Day 28
High Dose38.842.639.838.235.434.232.6
Low Dose49.422.621.031.632.225.625.8

Reviews

10 reviews available for khellin and Acne

ArticleYear
[Inflammatory dermatoses in skin of color].
    Dermatologie (Heidelberg, Germany), 2023, Volume: 74, Issue:2

    Topics: Acne Vulgaris; Dermatitis, Atopic; Humans; Hyperpigmentation; Keloid; Psoriasis; Rosacea; Skin Pigme

2023
Efficacy and safety of needle-free jet injector-assisted intralesional treatments in dermatology-a systematic review.
    Drug delivery and translational research, 2023, Volume: 13, Issue:6

    Topics: Acne Vulgaris; Dermatology; Fluorouracil; Humans; Keloid; Treatment Outcome; Triamcinolone Acetonide

2023
Dermatologic Conditions in Transgender Populations.
    Endocrinology and metabolism clinics of North America, 2019, Volume: 48, Issue:2

    Topics: Acne Vulgaris; Alopecia; Hirsutism; Hormone Replacement Therapy; Humans; Keloid; Sex Reassignment Pr

2019
Acne Scar Treatment: A Multimodality Approach Tailored to Scar Type.
    Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2016, Volume: 42 Suppl 2

    Topics: Acne Vulgaris; Chemexfoliation; Cicatrix; Cicatrix, Hypertrophic; Combined Modality Therapy; High-In

2016
Acne Scar Treatment: A Multimodality Approach Tailored to Scar Type.
    Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2016, Volume: 42 Suppl 2

    Topics: Acne Vulgaris; Chemexfoliation; Cicatrix; Cicatrix, Hypertrophic; Combined Modality Therapy; High-In

2016
Acne Scar Treatment: A Multimodality Approach Tailored to Scar Type.
    Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2016, Volume: 42 Suppl 2

    Topics: Acne Vulgaris; Chemexfoliation; Cicatrix; Cicatrix, Hypertrophic; Combined Modality Therapy; High-In

2016
Acne Scar Treatment: A Multimodality Approach Tailored to Scar Type.
    Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2016, Volume: 42 Suppl 2

    Topics: Acne Vulgaris; Chemexfoliation; Cicatrix; Cicatrix, Hypertrophic; Combined Modality Therapy; High-In

2016
New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group.
    Journal of the American Academy of Dermatology, 2009, Volume: 60, Issue:5 Suppl

    Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Algorithms; Anti-Bacterial Agents; Chr

2009
New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group.
    Journal of the American Academy of Dermatology, 2009, Volume: 60, Issue:5 Suppl

    Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Algorithms; Anti-Bacterial Agents; Chr

2009
New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group.
    Journal of the American Academy of Dermatology, 2009, Volume: 60, Issue:5 Suppl

    Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Algorithms; Anti-Bacterial Agents; Chr

2009
New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group.
    Journal of the American Academy of Dermatology, 2009, Volume: 60, Issue:5 Suppl

    Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Algorithms; Anti-Bacterial Agents; Chr

2009
New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group.
    Journal of the American Academy of Dermatology, 2009, Volume: 60, Issue:5 Suppl

    Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Algorithms; Anti-Bacterial Agents; Chr

2009
New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group.
    Journal of the American Academy of Dermatology, 2009, Volume: 60, Issue:5 Suppl

    Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Algorithms; Anti-Bacterial Agents; Chr

2009
New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group.
    Journal of the American Academy of Dermatology, 2009, Volume: 60, Issue:5 Suppl

    Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Algorithms; Anti-Bacterial Agents; Chr

2009
New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group.
    Journal of the American Academy of Dermatology, 2009, Volume: 60, Issue:5 Suppl

    Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Algorithms; Anti-Bacterial Agents; Chr

2009
New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group.
    Journal of the American Academy of Dermatology, 2009, Volume: 60, Issue:5 Suppl

    Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Algorithms; Anti-Bacterial Agents; Chr

2009
New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group.
    Journal of the American Academy of Dermatology, 2009, Volume: 60, Issue:5 Suppl

    Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Algorithms; Anti-Bacterial Agents; Chr

2009
New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group.
    Journal of the American Academy of Dermatology, 2009, Volume: 60, Issue:5 Suppl

    Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Algorithms; Anti-Bacterial Agents; Chr

2009
New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group.
    Journal of the American Academy of Dermatology, 2009, Volume: 60, Issue:5 Suppl

    Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Algorithms; Anti-Bacterial Agents; Chr

2009
New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group.
    Journal of the American Academy of Dermatology, 2009, Volume: 60, Issue:5 Suppl

    Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Algorithms; Anti-Bacterial Agents; Chr

2009
New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group.
    Journal of the American Academy of Dermatology, 2009, Volume: 60, Issue:5 Suppl

    Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Algorithms; Anti-Bacterial Agents; Chr

2009
New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group.
    Journal of the American Academy of Dermatology, 2009, Volume: 60, Issue:5 Suppl

    Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Algorithms; Anti-Bacterial Agents; Chr

2009
New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group.
    Journal of the American Academy of Dermatology, 2009, Volume: 60, Issue:5 Suppl

    Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Algorithms; Anti-Bacterial Agents; Chr

2009
[Therapy of acne scars].
    Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2010, Volume: 8 Suppl 1

    Topics: Acne Vulgaris; Atrophy; Chemexfoliation; Cicatrix; Cicatrix, Hypertrophic; Dermabrasion; Evidence-Ba

2010
Cosmetic dermatologic surgery.
    Archives of dermatology, 1982, Volume: 118, Issue:12

    Topics: Acne Vulgaris; Alopecia; Chemexfoliation; Cicatrix; Collagen; Dermabrasion; Facial Dermatoses; Femal

1982
The therapeutic uses of topical vitamin A acid.
    Journal of the American Academy of Dermatology, 1981, Volume: 4, Issue:5

    Topics: Acne Vulgaris; Animals; Callosities; Cocarcinogenesis; Fox-Fordyce Disease; Humans; Ichthyosis; Kelo

1981
[Keloid or Hypertrophic scar?].
    Duodecim; laaketieteellinen aikakauskirja, 1996, Volume: 112, Issue:4

    Topics: Acne Vulgaris; Cicatrix, Hypertrophic; Diagnosis, Differential; Humans; Keloid; Risk Assessment; Wou

1996
[Therapy of skin and venereal diseases. Review of the literature of 1967-68].
    Deutsches medizinisches Journal, 1969, Volume: 20, Issue:15

    Topics: Acne Vulgaris; Alopecia; Balanitis; Candidiasis; Dermatitis, Occupational; Dermatomycoses; Diaper Ra

1969

Trials

2 trials available for khellin and Acne

ArticleYear
Cold anesthesia for pain reduction during intralesional steroid injection for nodulocystic acne.
    Journal of cosmetic dermatology, 2023, Volume: 22, Issue:12

    Topics: Acne Vulgaris; Anesthesia; Humans; Injections, Intralesional; Keloid; Pain; Steroids; Treatment Outc

2023
Treatment of inflamed hypertrophic scars using intralesional 5-FU.
    Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 1999, Volume: 25, Issue:3

    Topics: Acne Vulgaris; Adult; Aged; Anti-Inflammatory Agents; Antimetabolites; Cicatrix; Female; Fluorouraci

1999

Other Studies

35 other studies available for khellin and Acne

ArticleYear
Commentary on A Neglected Acne Scar Type: Papular Acne Scars and Their Correlations With Keloid Scars.
    Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2021, 10-01, Volume: 47, Issue:10

    Topics: Acne Vulgaris; Cicatrix; Cicatrix, Hypertrophic; Humans; Keloid

2021
Treatment of acne by subcutaneous injection of low-concentration 5-Fluorouracil.
    Journal of cosmetic dermatology, 2022, Volume: 21, Issue:8

    Topics: Acne Vulgaris; Fluorouracil; Humans; Injections, Intralesional; Injections, Subcutaneous; Keloid

2022
Spontaneous keloids during isotretinoin treatment for acne.
    Journal of cosmetic dermatology, 2022, Volume: 21, Issue:11

    Topics: Acne Vulgaris; Administration, Oral; Dermatologic Agents; Humans; Isotretinoin; Keloid; Treatment Ou

2022
Acne Scars: An Update on Management
    Skin therapy letter, 2022, Volume: 27, Issue:6

    Topics: Acne Vulgaris; Atrophy; Humans; Keloid; Quality of Life; Treatment Outcome; Wound Healing

2022
Acne Scars: An Update on Management
    Skin therapy letter, 2022, Volume: 27, Issue:6

    Topics: Acne Vulgaris; Atrophy; Humans; Keloid; Quality of Life; Treatment Outcome; Wound Healing

2022
Acne Scars: An Update on Management
    Skin therapy letter, 2022, Volume: 27, Issue:6

    Topics: Acne Vulgaris; Atrophy; Humans; Keloid; Quality of Life; Treatment Outcome; Wound Healing

2022
Acne Scars: An Update on Management
    Skin therapy letter, 2022, Volume: 27, Issue:6

    Topics: Acne Vulgaris; Atrophy; Humans; Keloid; Quality of Life; Treatment Outcome; Wound Healing

2022
Rare Complication of Massive Depigmentation After Postoperative Treatment of Giant Keloid Combined With Strontium-90.
    The Journal of craniofacial surgery, 2023, Sep-01, Volume: 34, Issue:6

    Topics: Acne Vulgaris; Adolescent; Humans; Keloid; Postoperative Period; Recurrence; Strontium Radioisotopes

2023
A massive mandibular keloid with severe infection: What is your treatment?
    Photodiagnosis and photodynamic therapy, 2021, Volume: 33

    Topics: Acne Vulgaris; Aminolevulinic Acid; Humans; Keloid; Photochemotherapy; Photosensitizing Agents; Trea

2021
[Atypical keloids with an unusual myofibroblastic differentiation in a patient with acne vulgaris].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2022, Volume: 73, Issue:3

    Topics: Acne Vulgaris; Adrenal Cortex Hormones; Cicatrix, Hypertrophic; Cryotherapy; Humans; Injections, Int

2022
A method of scar evaluation using non-contact 3D scanner.
    Computer methods in biomechanics and biomedical engineering, 2013, Volume: 16 Suppl 1

    Topics: Acne Vulgaris; Adult; Aged; Female; Humans; Imaging, Three-Dimensional; Keloid; Male; Middle Aged

2013
Observational retrospective study evaluating the effects of oral isotretinoin in keloids and hypertrophic scars.
    International journal of dermatology, 2016, Volume: 55, Issue:11

    Topics: Acne Vulgaris; Administration, Oral; Adolescent; Adult; Case-Control Studies; Cicatrix, Hypertrophic

2016
Health disparities in arthritis and musculoskeletal and skin diseases-the dermatology session: National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Maryland, December 15-16, 2000.
    Journal of the American Academy of Dermatology, 2002, Volume: 47, Issue:5

    Topics: Acne Vulgaris; Black People; Health Surveys; Humans; Keloid; Minority Groups; Racial Groups; Researc

2002
Carcinoma with adenomatous structure in skin transplanted in the region of keloid acne of the neck.
    Panminerva medica, 1960, Volume: 2

    Topics: Acne Vulgaris; Carcinoma; Head and Neck Neoplasms; Humans; Keloid; Neoplasms; Skin; Skin Transplanta

1960
An unusual case of acne keloid.
    Leprosy review, 1962, Volume: 33

    Topics: Acne Keloid; Acne Vulgaris; Humans; Keloid; Leprosy

1962
THE TREATMENT OF SKIN CONDITIONS IN THE RADIOTHERAPY DEPARTMENT.
    Radiography, 1963, Volume: 29

    Topics: Acne Vulgaris; Geriatrics; Hair Removal; Humans; Keloid; Keratosis; Neoplasms; Pruritus; Radiotherap

1963
[INTRALESIONAL EFFECTS OF BETAMETHASONE WITH SPECIAL REFERENCE TO ITS HISTOPATHOLOGIC STUDY].
    Prensa medica argentina, 1963, May-17, Volume: 50

    Topics: Acne Vulgaris; Betamethasone; Humans; Injections; Keloid; Leprosy; Lichen Planus; Lupus Erythematosu

1963
CLINICAL EVALUATION OF A STEROID-VITAMIN A-ESTROGEN LOTION.
    Journal of the American Medical Women's Association, 1963, Volume: 18

    Topics: Acne Vulgaris; Alopecia Areata; Dermatitis; Dermatitis, Atopic; Dermatology; Estrogens; Humans; Hydr

1963
Keloid associated with acne in a young girl.
    Proceedings of the Royal Society of Medicine, 1950, Volume: 43, Issue:3

    Topics: Acne Vulgaris; Female; Humans; Keloid

1950
Possible isotretinoin-induced keloids in a patient with Behçet's disease.
    Clinical and experimental dermatology, 2006, Volume: 31, Issue:4

    Topics: Acne Vulgaris; Adult; Behcet Syndrome; Drug Eruptions; Humans; Isotretinoin; Keloid; Keratolytic Age

2006
Prevalence of childhood acne, ephelides, warts, atopic dermatitis, psoriasis, alopecia areata and keloid in Kaohsiung County, Taiwan: a community-based clinical survey.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2007, Volume: 21, Issue:5

    Topics: Acne Vulgaris; Alopecia Areata; Chi-Square Distribution; Child; Cross-Sectional Studies; Dermatitis,

2007
Delayed type hypersensitivity reaction to cutaneous antigen in keloid.
    Indian journal of dermatology, 1982, Volume: 27, Issue:4

    Topics: Acne Vulgaris; Adolescent; Adult; Female; Humans; Hypersensitivity, Delayed; Isoantigens; Keloid; Ma

1982
[The diagnosis and treatment of hypertrophic and keloid scars].
    Klinicheskaia khirurgiia, 1994, Issue:9

    Topics: Acne Vulgaris; Burns; Cicatrix, Hypertrophic; Cryosurgery; Humans; Keloid; Skin

1994
Analysis of collagen composition in acne keloids.
    Biochemical Society transactions, 1993, Volume: 21 ( Pt 3), Issue:3

    Topics: Acne Vulgaris; Biopsy; Cell Division; Cells, Cultured; Collagen; Fibroblasts; Humans; Keloid; Procol

1993
Prevalence of acne keloidalis nuchae in football players.
    Journal of the American Academy of Dermatology, 1997, Volume: 37, Issue:4

    Topics: Acne Keloid; Acne Vulgaris; Adolescent; Adult; Age Factors; Analysis of Variance; Black People; Conf

1997
Keloid formation induced by isotretinoin therapy.
    International journal of dermatology, 1999, Volume: 38, Issue:3

    Topics: Acne Vulgaris; Adolescent; Humans; Isotretinoin; Keloid; Keratolytic Agents; Male

1999
A study of the spectrum of skin disease occurring in a black population in south-east London.
    The British journal of dermatology, 1999, Volume: 141, Issue:3

    Topics: Acne Vulgaris; Acrodermatitis; Adult; Black or African American; Black People; Child; Cohort Studies

1999
The place of intralesional steroid therapy in dermatology.
    The British journal of dermatology, 1976, Volume: 94 suppl 12

    Topics: Acne Vulgaris; Adult; Aged; Alopecia Areata; Humans; Injections, Jet; Keloid; Lupus Erythematosus, S

1976
[Roentgen therapy of dermatoses: indications and hazards].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 1978, Volume: 29, Issue:5

    Topics: Acne Vulgaris; Eczema; Foot Dermatoses; Humans; Keloid; Lichen Planus; Lymphocytosis; Neoplasms, Rad

1978
Radiotherapy of benign dermatoses: indications, practice, and results.
    The Journal of dermatologic surgery and oncology, 1978, Volume: 4, Issue:8

    Topics: Acne Vulgaris; Bacterial Infections; Dupuytren Contracture; Eczema; Female; Hemangioma; Herpes Simpl

1978
Acne keloidalis aggravated by football helmets.
    Cutis, 1992, Volume: 50, Issue:2

    Topics: Acne Vulgaris; Adult; Football; Head Protective Devices; Humans; Keloid; Male; Scalp Dermatoses

1992
[Dermabrasion--indications, technic, possibilities, complications].
    Zeitschrift fur Lymphologie. Journal of lymphology, 1985, Volume: 9, Issue:1

    Topics: Acne Vulgaris; Dermabrasion; Female; Humans; Keloid; Male; Rhinophyma; Tattooing

1985
Laser surgery for children.
    The Journal of dermatologic surgery and oncology, 1987, Volume: 13, Issue:2

    Topics: Acne Vulgaris; Child; Cicatrix; Hemangioma; Humans; Keloid; Laser Therapy; Pigmentation Disorders; S

1987
Delayed wound healing and keloid formation following argon laser treatment or dermabrasion during isotretinoin treatment.
    The British journal of dermatology, 1988, Volume: 118, Issue:5

    Topics: Acne Vulgaris; Adult; Aged; Dermabrasion; Female; Humans; Isomerism; Isotretinoin; Keloid; Laser The

1988
Experience with the Nd:YAG laser in the treatment of keloid scars.
    Annals of plastic surgery, 1988, Volume: 21, Issue:3

    Topics: Acne Vulgaris; Adolescent; Child; Cicatrix; Humans; Keloid; Laser Therapy; Male; Skin; Wound Healing

1988
Atypical keloids after dermabrasion of patients taking isotretinoin.
    Journal of the American Academy of Dermatology, 1986, Volume: 15, Issue:2 Pt 1

    Topics: Acne Vulgaris; Adult; Dermabrasion; Female; Humans; Isotretinoin; Keloid; Male; Microbial Collagenas

1986
Multiple keloids.
    Archives of dermatology, 1971, Volume: 104, Issue:1

    Topics: Acne Vulgaris; Adult; Aged; Black or African American; Female; Humans; Keloid; Male; Middle Aged; Sk

1971
Minor surgery for benign and malignant facial lesions.
    American family physician, 1974, Volume: 10, Issue:5

    Topics: Acne Vulgaris; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cicatrix; Cortisone; Curettage; Cyst

1974